ECSP22012347A - Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr - Google Patents

Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr

Info

Publication number
ECSP22012347A
ECSP22012347A ECSENADI202212347A ECDI202212347A ECSP22012347A EC SP22012347 A ECSP22012347 A EC SP22012347A EC SENADI202212347 A ECSENADI202212347 A EC SENADI202212347A EC DI202212347 A ECDI202212347 A EC DI202212347A EC SP22012347 A ECSP22012347 A EC SP22012347A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
alkyl
substituted
morpholinopyridine
derivatives
Prior art date
Application number
ECSENADI202212347A
Other languages
English (en)
Inventor
Paul Jones
Audrey Picard
Abbas Abdoli
Vouy Linh Truong
Cameron Black
Cyrus M Lacbay
Stéphanie Lanoix
Jean-François Truchon
Miguel St-Onge
Lee Fader
Stéphane Dorich
Sheldon N Crane
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2019/051539 external-priority patent/WO2020087170A1/en
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of ECSP22012347A publication Critical patent/ECSP22012347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos con la fórmula (I) o sales farmacéuticamente aceptables de estos, en donde - es un enlace simple, y cada Y es N o CR4; o - está ausente, y cada Y es NRY, carbonilo o (C(RY)2, en donde cada R1 es H o alquilo de C1-6 opcionalmente sustituido; R1 es alquilo de C1-6 opcionalmente sustituido o H; R3 es heteroarilo de C1-9 opcionalmente sustituido o alquilo de C1-6 heteroarilo de C1-9 opcionalmente sustituido; cada R4 es hidrógeno, halógeno, alquilo de C1-6 opcionalmente sustituido, alquenilo de C2-6 opcionalmente sustituido o alquinilo de C2-6 opcionalmente sustituido; X es hidrógeno o halógeno; y R2 es como se define en la reivindicación 1. También se describen composiciones farmacéuticas que contienen los compuestos con la fórmula (I) y métodos para su preparación. Los compuestos con la fórmula (I) pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD-3 (ATR) y usarse para el tratamiento de enfermedades y afecciones tales como cánceres.
ECSENADI202212347A 2019-07-22 2022-02-16 Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr ECSP22012347A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877177P 2019-07-22 2019-07-22
PCT/CA2019/051539 WO2020087170A1 (en) 2018-10-30 2019-10-30 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PCT/CA2020/051014 WO2021012049A1 (en) 2019-07-22 2020-07-22 Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors

Publications (1)

Publication Number Publication Date
ECSP22012347A true ECSP22012347A (es) 2022-03-31

Family

ID=74192632

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202212347A ECSP22012347A (es) 2019-07-22 2022-02-16 Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr

Country Status (16)

Country Link
US (1) US20220185809A1 (es)
EP (1) EP4003993A4 (es)
JP (2) JP7617076B2 (es)
KR (1) KR20220035925A (es)
CN (1) CN114174292B (es)
AU (1) AU2020317381A1 (es)
BR (1) BR112022000431A2 (es)
CA (1) CA3148278A1 (es)
CO (1) CO2022001853A2 (es)
CR (1) CR20220068A (es)
EC (1) ECSP22012347A (es)
IL (1) IL289763A (es)
MX (1) MX2022000854A (es)
PH (1) PH12022550156A1 (es)
UA (1) UA129807C2 (es)
WO (1) WO2021012049A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
CN115103677A (zh) * 2019-12-11 2022-09-23 修复治疗公司 Atr抑制剂与parp抑制剂的组合的用途
US20240392379A1 (en) * 2021-04-28 2024-11-28 Repare Therapeutics Inc. Methods of treating cancers having a biallelic loss of function or gene overexpression mutation
CN117794931A (zh) * 2021-06-04 2024-03-29 修复治疗公司 结晶形式、包含其的组合物及它们的使用方法
IL310412A (en) * 2021-07-27 2024-03-01 Littdd Medicines Ltd 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN113856764B (zh) * 2021-10-29 2022-11-01 华中科技大学 一种过渡金属催化剂及其制备方法和应用
CN116099390B (zh) * 2022-11-14 2024-07-23 石河子大学 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用
WO2024211696A1 (en) * 2023-04-07 2024-10-10 Biogen Ma Inc. 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025067111A1 (zh) * 2023-09-27 2025-04-03 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025181153A1 (en) * 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025239794A1 (en) * 2024-05-15 2025-11-20 Joint Stock Company “Biocad” Ataxia telangiectasia and rad3-related inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025504T2 (en) * 2009-12-31 2016-02-29 Hutchison Medipharma Ltd Certain triazolopyrazines, compositions thereof and methods of use therefor
ES2528269T3 (es) * 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2013039988A1 (en) * 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
KR20170140382A (ko) * 2015-04-29 2017-12-20 얀센 파마슈티카 엔.브이. 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도
WO2017121684A1 (en) * 2016-01-14 2017-07-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
AU2020317381A1 (en) 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors

Also Published As

Publication number Publication date
JP2025061048A (ja) 2025-04-10
JP2022541825A (ja) 2022-09-27
CR20220068A (es) 2022-06-30
EP4003993A4 (en) 2023-01-18
CA3148278A1 (en) 2021-01-28
WO2021012049A1 (en) 2021-01-28
PH12022550156A1 (en) 2023-05-08
JP7758895B2 (ja) 2025-10-22
EP4003993A1 (en) 2022-06-01
IL289763A (en) 2022-03-01
WO2021012049A8 (en) 2021-04-15
CO2022001853A2 (es) 2022-03-29
AU2020317381A1 (en) 2022-02-10
BR112022000431A2 (pt) 2022-03-03
JP7617076B2 (ja) 2025-01-17
UA129807C2 (uk) 2025-08-06
US20220185809A1 (en) 2022-06-16
CN114174292A (zh) 2022-03-11
KR20220035925A (ko) 2022-03-22
MX2022000854A (es) 2022-02-10
CN114174292B (zh) 2024-06-18

Similar Documents

Publication Publication Date Title
ECSP22012347A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
AR130689A1 (es) Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
UY26968A1 (es) Agentes terapéuticos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
CL2012001699A1 (es) Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos, inhibidores de cfms; proceso de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de enfermedades relacionadas con huesos, cancer, trastornos autoinmunes, enfermedades inflamatorias, entre otras.
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
AR040580A1 (es) Derivados de pirazol heterobiciclico como inhibidores de la quinasa
ZA202002762B (en) Benzimidazole derivatives and their uses
MX389581B (es) Compuestos que contienen nitrogeno sustituido.
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.